Details of blood coagulation factors II, VII, IX and more; the coagulation cascade; haemorrhagic risk assessment, using the international normalised ratio; the factor Xa inhibitors rivaroxaban, edoxaban or apixaban; the factor IIa (thrombin) inhibitor dabigatran; the risks of warfarin treatment; current national and international guidelines; the use of fresh frozen plasma to reverse vitamin K antagonist (VKA) anticoagulation; plasma and rVIIA; and details of the anticoagulation reversal agents idarucizumab, andexanet alpha and ciraparantag are all included in this section.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest